Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human GRK2 ELISA Kit (AC3953)
Cat.#: ASET-2542
Specifications
Description Human GRK2 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human GRK2 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 4.95 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 75-1200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1170 Human LMOD1 ELISA Kit (AC2581) Quantitative inquiry ASET-1308 Human Eph Receptor A2 ELISA Kit (AC2719) Quantitative inquiry ASET-2464 Human CRY2 ELISA Kit (AC3875) Quantitative inquiry ASET-1201 Rat MAP2 ELISA Kit (AC2612) Quantitative inquiry ASET-1400 Mouse Semaphorin 3A ELISA Kit (AC2811) Quantitative inquiry ASET-1057 Human COMT ELISA Kit (AC2468) Quantitative inquiry ASET-1897 Mouse Estrogen Receptor beta ELISA Kit (AC3308) Quantitative inquiry ASET-2094 Mouse VMAT2 ELISA Kit (AC3505) Quantitative inquiry ASET-1963 Human MDGA2 ELISA Kit (AC3374) Quantitative inquiry ASET-2364 Human Glutaminase ELISA Kit (AC3775) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket